SEC Form 4 · accession 0000899243-17-008992
Wave Life Sciences, Inc. · WVE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Masaharu Tanaka
Director · 10% Owner
Period of report
Mar 29, 2017
Accepted (ET)
Mar 31, 2017 · 3:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631574
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Mar 29, 2017 | S | 433,825 | $24.91 | D | 2,794,865 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The aggregate purchase price for the 433,825 Ordinary Shares was 1,199,998,712 Japanese yen. The purchase price per share in Column 4 of Table I was calculated based on the aggregate purchase price divided by the number of Ordinary Shares sold. The purchase price per share is shown in U.S. dollars and was converted based on the currency exchange rate as of the transaction date, March 29, 2017, rounded to the nearest whole cent.
- F2Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka, a director of the Issuer, is the representative director of Kagoshima Development Co., Ltd., the general partner of KSS and may be deemed to beneficially own the reported securities. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Tanaka disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.